GenMark's Q4 Revenues Spike 157 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market on Thursday that its fourth-quarter revenues more than doubled year over year, led by a 156 percent spike in reagent sales.

For the three months ended Dec. 31, 2010, the Carlsbad, Calif.-based firm posted $787,482 in revenues, up 157 percent from $306,410 a year ago and above a Wall Street forecast of $690,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.